Delayed trial readouts

Studies whose primary completion date moved on ClinicalTrials.gov in the last 180 days, newest first. The primary completion date is the sponsor's own estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout. Our daily registry check records each move the day it sees it. Upcoming dates are on the readout calendar.

Summary

521 date moves in Phase 3 and 2/3 studies: 323 later and 198 earlier. The median move later is 183 days.

Date moves

SeenDrugStudyPhaseOld dateNew dateMove
2026-11-20aldesleukinNCT01704716High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Phase 32021-09-302025-01-30+1218 days
2026-11-20Capecitabine, Gemcitabine, Eribulin mesylateNCT06143553Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast CancerPhase 32025-122027-12-31+760 days
2026-11-20Semaglutide (Ozempic)NCT06387199Alleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous SemaglutidePhase 2/32027-012027-12+334 days
2026-11-20LetrozoleNCT04111978MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)Phase 32027-07-012028-02-01+215 days
2026-11-20Rifaximin SSDNCT05071716Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in CirrhosisPhase 32025-092025-12-23+113 days
2026-11-20Zoledronic acidNCT03295981Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of BonePhase 32027-012027-04+90 days
2026-11-20Oxycodone (Xtampza ER)NCT03823534Post-Op Pain Control for Prophylactic Intramedullary Nailing.Phase 32026-12-312027-03-31+90 days
2026-11-20GoserelinNCT07777263ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)Phase 32035-102035-12+61 days
2026-11-20Semaglutide (Wegovy)NCT07845994SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 YearsPhase 32031-022031-03+28 days
2026-11-19AnakinraNCT05805930Therapeutic Approach in Colchicine-resistant Recurrent pEricarditis in ChildrenPhase 32025-06-012027-10-01+852 days
2026-11-19PovetaciceptNCT07204275Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)Phase 2/32028-12-292029-06-27+180 days
2026-11-19AND017NCT07494409A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With AnemiaPhase 32026-10-302027-02-20+113 days
2026-11-19AND017NCT07487727A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)Phase 32026-12-012027-03-01+90 days
2026-11-19Dexamethasone, Cevostamab, Elotuzumab, Pomalidomide, Daratumumab, CarfilzomibNCT07555938Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaPhase 32028-10-312028-11-30+30 days
2026-11-19Depemokimab, MepolizumabNCT05263934Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)Phase 32026-09-292026-10-06+7 days
2026-11-18tenofovir alafenamide (Vemlidy), lamivudine (Epivir-HBV), Tenofovir disoproxil fumarate (Viread), Doravirine, BictegravirNCT07075146DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or ObesityPhase 32026-06-052027-12-05+548 days
2026-11-18Methotrexate, etanerceptNCT03728478STep-up and Step-down Therapeutic Strategies in Childhood ARthritiSPhase 32025-02-282025-10-31+245 days
2026-11-18faricimabNCT06790784Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDRPhase 32031-082032-02+184 days
2026-11-18viloxazineNCT02736656Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)Phase 32026-092026-12+91 days
2026-11-18TemozolomideNCT07935889Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 TrialPhase 32035-11-022035-11-30+28 days
2026-11-17zasocitinibNCT07250802A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque PsoriasisPhase 32033-01-242034-07-03+525 days
2026-11-17Iparomlimab and tuvonralimabNCT07613567QL1706 Combined With Chemotherapy as Neoadjuvant Therapy for High-Risk Locally Advanced Cervical CancerPhase 32032-08-312032-12-31+122 days
2026-11-17HRG2010NCT06596876A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor FluctuationsPhase 32025-10-092026-01-29+112 days
2026-11-17DostarlimabNCT07740720A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal CancerPhase 32029-12-122030-03-13+91 days
2026-11-14Rosuvastatin, LaroprovstatNCT06834932A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaPhase 2/32025-07-032027-02-22+599 days
2026-11-14Omega-3-acid ethyl esters (Lovaza)NCT02178410VITAL Rhythm StudyPhase 32026-102027-10+365 days
2026-11-14upadacitinibNCT05889182A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF TherapyPhase 32028-032028-08+153 days
2026-11-14Trastuzumab Emtansine, InavolisibNCT05894239A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 32026-12-312027-05-03+123 days
2026-11-14ADSTEMNCT07377838Study of ADSTEM Injection for Patients With Moderate to Severe Subacute and Chronic Atopic DermatitisPhase 32029-062029-09+92 days
2026-11-14SuzetrigineNCT07654296Assessing Suzetrigine for Pain Reduction Following Ureteroscopic SurgeryPhase 32026-12-312027-03-31+90 days
2026-11-13MethylprednisoloneNCT05139849VAsopressin and STeroids in Addition to Adrenaline in Cardiac Arrest - a Randomized Clinical TrialPhase 32027-01-312029-01-31+731 days
2026-11-13Docetaxel, OSE2101NCT06472245Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorPhase 32027-12-152028-05-01+138 days
2026-11-13VadadustatNCT06520826Vafseo Outcomes In-Center ExperiencePhase 32026-06-302026-09-10+72 days
2026-11-13EverolimusNCT02962414Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued TreatmentPhase 32026-12-302027-02-26+58 days
2026-11-13GemcitabineNCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNAPhase 2/32029-01-012029-01-31+30 days
2026-11-13Odronextamab, RituximabNCT06091254A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaPhase 32028-02-072028-02-29+22 days
2026-11-13Ruxolitinib (Opzelura)NCT06959225Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)Phase 32026-10-092026-10-29+20 days
2026-11-11MethotrexateNCT02205762LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell HistiocytosisPhase 2/32026-072031-11+1949 days
2026-11-11Fianlimab, Cemiplimab, PembrolizumabNCT05608291A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryPhase 32026-07-272027-01-15+172 days
2026-11-11zenagamtide, Semaglutide (Ozempic)NCT07400107AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightPhase 32028-12-122028-12-19+7 days
2026-11-10IncobotulinumtoxinA (Xeomin)NCT00909883Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)Phase 32011-092013-11-12+803 days
2026-11-08BosentanNCT02377271ENDOTHELION Study Group: Effect of Bosentan in NAION PatientsPhase 32023-122027-02+1158 days
2026-11-08Tarlatamab, DurvalumabNCT06211036Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabPhase 32027-07-052030-04-02+1002 days
2026-11-08Olanzapine (Zyprexa)NCT06200181Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control TrialPhase 32026-11-012027-11-01+365 days
2026-11-08PertuzumabNCT02320435A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical TrialPhase 32026-12-312027-03-28+87 days
2026-11-08BevacizumabNCT07851025Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian CancerPhase 32030-06-182030-06-28+10 days
2026-11-07Famitinib, CamrelizumabNCT05999149A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)Phase 32025-08-302026-05-30+273 days
2026-11-07DostarlimabNCT05201547Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First LinePhase 32026-042026-10-01+183 days
2026-11-07FampridineNCT06136728Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple SclerosisPhase 32026-122027-05+151 days
2026-11-07ZiltivekimabNCT06263244Specifying the Anti-inflammatory Effects of ZiltivekimabPhase 32026-09-042026-10-30+56 days
2026-11-06baricitinibNCT05056558Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19Phase 32022-042025-07-30+1216 days
2026-11-06DexamethasoneNCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)Phase 32028-08-022028-11-30+120 days
2026-11-06Aflibercept, Tabirafusp tedromer, Tarcocimab tedromerNCT06556368A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAKPhase 32026-082026-09-02+32 days
2026-11-06Furosemide (subcutaneous, SQ Innovation)NCT07018297Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart FailurePhase 32028-08-012028-09-01+31 days
2026-11-06maridebart cafraglutide, Semaglutide (Ozempic)NCT07866066Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesPhase 32028-09-042028-09-06+2 days
2026-11-05Hydroxychloroquine, Dexamethasone, apremilast, tocilizumab, Sarilumab, Anakinra, baricitinibNCT02735707Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPhase 32026-022028-06+851 days
2026-11-05Sintilimab, Nab-paclitaxelNCT05429463Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ)Phase 32025-11-112026-11-30+384 days
2026-11-05Sotagliflozin (Inpefa)NCT07211802CKM For Safe Use of SGLT2i in Type 1 DiabetesPhase 32030-07-312031-07-31+365 days
2026-11-05metforminNCT06452498Preeclampsia Intervention NetherlandsPhase 32028-042029-03-19+352 days
2026-11-05Rituximab, NivolumabNCT04759586Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaPhase 32026-12-312027-06-30+181 days
2026-11-05Monalizumab, Oleclumab, DurvalumabNCT05221840A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerPhase 32026-09-302027-01-08+100 days
2026-11-05DapagliflozinNCT07295223Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)Phase 32026-082026-10-30+90 days
2026-11-05Albuterol sulfate (Proventil HFA), albuterol (Armstrong Albuterol HFA), fluticasone propionateNCT06052267A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma ExacerbationsPhase 32026-10-312026-12-31+61 days
2026-11-05Risdiplam (Evrysdi)NCT05115110A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyPhase 2/32026-10-282026-11-02+5 days
2026-11-04metforminNCT04177303Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin TreatmentPhase 32022-11-292024-12-31+763 days
2026-11-04jaktinibNCT05676242A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic DermatitisPhase 32024-122026-03-12+466 days
2026-11-04dupilumabNCT02612454Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)Phase 32026-10-072026-10-09+2 days
2026-11-03FurmonertinibNCT05607550Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)Phase 32025-08-152026-10-06+417 days
2026-11-03HydroxychloroquineNCT05287321The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for PreeclampsiaPhase 32026-12-312027-12-31+365 days
2026-11-01RituximabNCT03560011Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic SyndromePhase 2/32021-01-072022-11-04+666 days
2026-11-01Bemdaneprocel (MSK-DA01)NCT06944522A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's DiseasePhase 32027-032028-10+580 days
2026-11-01BevacizumabNCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)Phase 32029-12-172030-07-22+217 days
2026-11-01PumitamigNCT06616532PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung CancerPhase 32027-01-252027-05+96 days
2026-11-01N-acetylcysteine, metforminNCT06836128The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome PatientsPhase 32026-02-012026-03-30+57 days
2026-11-01BevacizumabNCT07816666Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerPhase 32028-09-262028-09-29+3 days
2026-11-01Goserelin, Methylprednisolone, DocetaxelNCT04787744Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerPhase 2/32026-09-302026-10-02+2 days
2026-10-31Vigabatrin (Sabril)NCT04987463Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in InfantsPhase 2/32026-032028-12+1006 days
2026-10-31Trastuzumab pamirtecan, Trastuzumab EmtansineNCT06265428A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast CancerPhase 32026-022027-12+668 days
2026-10-31metforminNCT05468554Evaluation of Metformin Effect on the Fertility of Women Treated With 131I for Thyroid CancerPhase 32026-04-302028-01-31+641 days
2026-10-31SintilimabNCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)Phase 2/32025-012026-08-28+604 days
2026-10-31MevrometostatNCT06629779A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.Phase 32026-12-022027-09-30+302 days
2026-10-31Dexamethasone, Rituximab, MethotrexateNCT03150693Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaPhase 32027-03-012027-11-01+245 days
2026-10-31Rifaximin (Xifaxan)NCT07522255Rifaximin Treatment in Bloating Predominant Functional Bowel DisordersPhase 32027-102028-06+244 days
2026-10-31TricaprilinNCT05809908Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) StudyPhase 32029-062030-01+214 days
2026-10-31DocetaxelNCT04784715Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Phase 32026-11-112027-05-03+173 days
2026-10-31Adebrelimab, BevacizumabNCT07691762A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaPhase 32031-042031-09+153 days
2026-10-31Rituximab, VenetoclaxNCT03984448Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell LymphomasPhase 2/32028-04-012028-08-13+134 days
2026-10-31TelikibartNCT06516302A Study of GR1802 in Participants With Chronic Sinusitis With Nasal PolypsPhase 32026-032026-06-12+103 days
2026-10-31Mevrometostat, DocetaxelNCT06551324A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).Phase 32026-12-282027-02-28+62 days
2026-10-31AmmoxetineNCT06827431The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With DepressionPhase 32026-06-302026-07-14+14 days
2026-10-29Trastuzumab DeruxtecanNCT06174987A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)Phase 32026-08-032028-02-17+563 days
2026-10-29hepalatideNCT07309380Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis DPhase 32027-062028-06+366 days
2026-10-29GabapentinNCT04724252Gabapentin to Reduce Opioid Use Postoperatively (GROUP) in ChildrenPhase 2/32026-12-312027-12-31+365 days
2026-10-29Ferric derisomaltoseNCT05407987Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)Phase 32026-12-302027-12-30+365 days
2026-10-29PembrolizumabNCT04534205A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1Phase 2/32028-082029-04+243 days
2026-10-29lebrikizumabNCT06339008A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)Phase 32026-092026-10-22+51 days
2026-10-29LenbelintideNCT07784270A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or OverweightPhase 32028-08-082028-08-09+1 day
2026-10-28survodutideNCT07855900SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightPhase 32028-06-252029-11-06+499 days
2026-10-28Ordastobart, PembrolizumabNCT06295731Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)Phase 2/32029-052029-12+214 days
2026-10-27Staccato AlprazolamNCT05077904A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresPhase 32026-10-312027-03-29+149 days
2026-10-27Cabotegravir/rilpivirine (Cabenuva)NCT06507059Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting AntiretroviralsPhase 32025-07-012025-08-06+36 days
2026-10-27DapagliflozinNCT06783166Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart FailurePhase 2/32025-07-012025-07-04+3 days
2026-10-26EverolimusNCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)Phase 2/32025-012026-08-28+604 days
2026-10-26IpilimumabNCT03793166Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyPhase 32028-01-252028-03-01+36 days
2026-10-26RavulizumabNCT07596784Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)Phase 32027-08-172027-08-24+7 days
2026-10-24PembrolizumabNCT03711032Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)Phase 32026-07-312028-07-31+731 days
2026-10-24Rimegepant (Nurtec ODT)NCT06616194A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent MigrainePhase 32028-08-192030-02-26+556 days
2026-10-24metforminNCT04578652Fiber and Metformin Combination Therapy in Adolescents With Severe Obesity and Insulin ResistancePhase 32026-092027-02+153 days
2026-10-24TolvaptanNCT04782258A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)Phase 32028-07-312028-12-28+150 days
2026-10-24Exemestane, Letrozole, Anastrozole, Tamoxifen (Soltamox)NCT04906395Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerPhase 32026-11-302027-01-30+61 days
2026-10-23GemcitabineNCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)Phase 32029-12-172030-07-22+217 days
2026-10-23Pertuzumab, Trastuzumab DeruxtecanNCT04784715Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Phase 32026-11-112027-05-03+173 days
2026-10-23HB0017NCT06477237Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque PsoriasisPhase 32024-082024-11-15+106 days
2026-10-22Capecitabine, Eribulin mesylate, Sacituzumab Tirumotecan, Nab-paclitaxelNCT06279364A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerPhase 32026-072027-04+274 days
2026-10-22AZD0120, LenalidomideNCT07735637A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).Phase 32028-10-112028-11-02+22 days
2026-10-21N-acetylcysteineNCT03900988Intravenous N-acetylcysteine and Oseltamivir Versus Oseltamivir in Adults Hospitalized With Influenza and PneumoniaPhase 32025-10-312027-10-31+730 days
2026-10-21Fruquintinib, AxitinibNCT05522231Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)Phase 2/32025-012026-08-28+604 days
2026-10-20Cetuximab, PembrolizumabNCT06589804Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentPhase 32029-11-302032-12-25+1121 days
2026-10-20Gemcitabine, pemetrexed, PembrolizumabNCT04267848Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 32027-01-312030-01-31+1096 days
2026-10-20metforminNCT06763328Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing ChemotherapyPhase 32029-06-162031-06-16+730 days
2026-10-20AfrezzaNCT06535789Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational DiabetesPhase 2/32025-072026-09-05+431 days
2026-10-20Dexamethasone, Etentamig, Lenalidomide, DaratumumabNCT07095452A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for TransplantPhase 2/32040-092041-03+181 days
2026-10-20tanruprubartNCT07020819An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)Phase 32026-12-312027-05-31+151 days
2026-10-20tradipitantNCT06836557Open Label Safety Study of Tradipitant in Idiopathic and Diabetic GastroparesisPhase 32025-122026-03-30+119 days
2026-10-20PembrolizumabNCT03244384Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial CancerPhase 32026-10-312027-01-01+62 days
2026-10-20Nivolumab, CabozantinibNCT03793166Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyPhase 32028-01-252028-03-01+36 days
2026-10-17upadacitinibNCT06332534Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's DiseasePhase 32027-062031-01+1310 days
2026-10-17DapagliflozinNCT05944016Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult PatientsPhase 32026-092027-09+365 days
2026-10-17Eptinezumab (Vyepti)NCT04965675A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic MigrainePhase 32026-09-052027-03-26+202 days
2026-10-17dupilumab, upadacitinibNCT06389136A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabPhase 32026-082026-11+92 days
2026-10-17deucravacitinibNCT04908202A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic DrugsPhase 32024-09-052024-10-10+35 days
2026-10-17nemolizumabNCT07762833Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic DermatitisPhase 32027-09-282027-10-28+30 days
2026-10-16Dapagliflozin, metforminNCT05601336Dapagliflozin Versus Metformin and Their Combination in Polycystic Ovary SyndromePhase 32023-07-302026-05-01+1006 days
2026-10-16BGM0504NCT06716203A Study of BGM0504 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and ExercisePhase 32025-12-292026-11-14+320 days
2026-10-16BGM0504, Semaglutide (Ozempic)NCT06716216A Study of BGM0504 in Participants With Type 2 DiabetesPhase 32026-03-202026-11-14+239 days
2026-10-16PembrolizumabNCT07286266A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)Phase 32029-12-172030-07-22+217 days
2026-10-16BGM0504NCT06704581A Study of BGM0504 Injection in Participants With Obesity or OverweightPhase 32025-11-272026-03-17+110 days
2026-10-16pemetrexed, Datopotamab Deruxtecan, OsimertinibNCT06417814A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerPhase 32026-09-302027-01-11+103 days
2026-10-15Docetaxel, GoserelinNCT03678025Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerPhase 32028-04-012033-04-01+1826 days
2026-10-15SomatropinNCT06103513Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in ChildrenPhase 32025-06-102028-01-05+939 days
2026-10-15Apatinib, CamrelizumabNCT05062837Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCCPhase 2/32024-09-302026-12-30+821 days
2026-10-15GemcitabineNCT02135042Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNAPhase 2/32026-12-012029-01-01+762 days
2026-10-15GemcitabineNCT04574960Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)Phase 32026-122027-12+365 days
2026-10-15Trastuzumab EmtansineNCT05296798A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Phase 32027-10-312028-06-15+228 days
2026-10-15Pumitamig, AtezolizumabNCT06712355Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung CancerPhase 32028-122029-04+121 days
2026-10-15Capsaicin (Qutenza)NCT06023706Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.Phase 32027-01-082027-05-08+120 days
2026-10-15Aripiprazole (Abilify), Cariprazine (QLM1016)NCT06799559Study on the Efficacy and Safety of QLM1016 in SchizophreniaPhase 32026-072026-10-23+114 days
2026-10-15VenetoclaxNCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPhase 32027-01-312027-04-30+89 days
2026-10-15AR1001NCT05531526Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)Phase 32026-052026-06-29+59 days
2026-10-15PelacarsenNCT07625306Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARLPhase 32028-12-072029-01-22+46 days
2026-10-15remibrutinibNCT07665437An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HSPhase 32031-10-242031-10-29+5 days
2026-10-15remibrutinibNCT06846281Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 32029-07-242029-07-25+1 day
2026-10-14Denosumab (Prolia)NCT04547348The DENOCHARCOT TrialPhase 32025-10-012030-08-01+1765 days
2026-10-14Cemiplimab, Nivolumab, Pembrolizumab, AtezolizumabNCT05317858Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsPhase 32027-06-012031-06-01+1461 days
2026-10-14LetrozoleNCT05316935GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia PatientsPhase 2/32026-03-302028-03-30+731 days
2026-10-14LetrozoleNCT06379113GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer PatientsPhase 2/32026-03-302028-03-30+731 days
2026-10-14AficamtenNCT04848506Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCMPhase 2/32028-032029-03+365 days
2026-10-14NivolumabNCT06022861A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell CarcinomaPhase 32025-062026-05-17+350 days
2026-10-14BGM0504, Semaglutide (Ozempic)NCT07064486A Study of BGM0504 in Participants With Type 2 Diabetes in IndonesiaPhase 32026-07-312027-04-30+273 days
2026-10-14DocetaxelNCT03178552A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Phase 2/32026-10-312027-06-30+242 days
2026-10-14AzetukalnerNCT06775379A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderPhase 32026-082026-10+61 days
2026-10-14onabotulinumtoxinANCT05878951Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder SymptomsPhase 2/32026-09-012026-10+30 days
2026-10-14DocetaxelNCT05132075Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerPhase 32026-08-252026-09-03+9 days
2026-10-13ObinutuzumabNCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPhase 32027-01-312027-04-30+89 days
2026-10-12AcalabrutinibNCT03836261Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLPhase 32027-01-312027-04-30+89 days
2026-10-10AlixorextonNCT06767683A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaPhase 2/32028-062030-06+730 days
2026-10-10Sacubitril/valsartanNCT06693674Effect of Sacubitril-Valsartan on Cardiac Structure and FunctionPhase 32026-122028-08+609 days
2026-10-10garetosmabNCT07559513A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)Phase 32028-12-102030-07-08+575 days
2026-10-10ZimislecelNCT04786262A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 DiabetesPhase 32027-06-302027-12-31+184 days
2026-10-10metforminNCT02275845Medico-GDM Trial - Metformine to Prevent Gestational Diabetes MellitusPhase 32016-092017-03-03+183 days
2026-10-09AzetukalnerNCT05716100A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)Phase 32026-102028-01+457 days
2026-10-07VildagliptinNCT02849899Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant PeriodPhase 32024-072026-06-05+704 days
2026-10-07VonaprumentNCT06510816A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)Phase 32026-10-312027-07-31+273 days
2026-10-07fluticasone propionateNCT06664619A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaPhase 32026-09-192026-11-02+44 days
2026-10-07ElismetrepNCT07816367A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of MigrainePhase 32027-092027-10+30 days
2026-10-07tilrekimig, dupilumabNCT07783425A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaPhase 32028-08-292028-09-08+10 days
2026-10-06Telisotuzumab Adizutecan, pemetrexed, OsimertinibNCT07005102A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerPhase 2/32031-122036-11+1797 days
2026-10-06AbemaciclibNCT04967521SARC041: Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated LiposarcomaPhase 32025-122027-12+730 days
2026-10-06FinerenoneNCT06058585The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectPhase 32028-08-302029-12-31+488 days
2026-10-06Haloperidol, Olanzapine (Zyprexa)NCT04833023HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled TrialPhase 32024-122025-09-25+298 days
2026-10-03Exemestane, Letrozole, Fulvestrant, Everolimus, AnastrozoleNCT07024173A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerPhase 32026-122027-08+243 days
2026-10-03Giredestrant, Docetaxel, PertuzumabNCT05296798A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Phase 32027-12-312028-06-15+167 days
2026-10-03IsatuximabNCT07732712Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma CellsPhase 2/32028-08-012028-12-31+152 days
2026-10-02DapagliflozinNCT06759077Cardio Protective Effect of SGL2I in Hemodialysis Patients and Its Impact on Patient Quality of LifePhase 32024-12-282026-03-28+455 days
2026-10-02TretinoinNCT06447480Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color PatientsPhase 32026-09-012027-09-01+365 days
2026-10-02Ipilimumab, NivolumabNCT07338981The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.Phase 32030-122031-12+365 days
2026-10-02elecoglipronNCT07775404A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusPhase 32027-06-042028-04-06+307 days
2026-10-02etanerceptNCT06596772A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [Proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid ArthritisPhase 32025-102026-02-20+142 days
2026-10-01Eptinezumab (Vyepti)NCT06428838Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency ContextPhase 32025-12-302028-03+792 days
2026-10-01pemetrexed, Tremelimumab, DurvalumabNCT04585490Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLCPhase 32026-082026-12+122 days
2026-09-30TemozolomideNCT05685004Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)Phase 2/32026-122030-11+1431 days
2026-09-30Lenacapavir (Sunlenca), BictegravirNCT06532656Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1Phase 2/32026-112030-07+1338 days
2026-09-30NivolumabNCT03811015Testing Immunotherapy Versus Observation in Patients With HPV Throat CancerPhase 32027-01-012030-01-31+1126 days
2026-09-30Bevacizumab, OsimertinibNCT04181060Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 32026-12-312029-06-30+912 days
2026-09-30Exemestane, Letrozole, Anastrozole, Tamoxifen (Soltamox)NCT04906395Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerPhase 32026-04-302026-11-30+214 days
2026-09-30NivolumabNCT02595944Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)Phase 32026-12-312027-05-31+151 days
2026-09-30Ipilimumab, NivolumabNCT03604991Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgeryPhase 2/32026-12-312027-03-31+90 days
2026-09-30Giredestrant, Docetaxel, PertuzumabNCT05296798A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)Phase 32027-10-312027-12-31+61 days
2026-09-30Staccato AlprazolamNCT05077904A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresPhase 32026-09-302026-10-31+31 days
2026-09-29Epirubicin, DocetaxelNCT05901428TCb vs EC-T in High Risk ER+/HER2- Breast CancerPhase 32026-062029-06+1096 days
2026-09-29PF-08634404, NivolumabNCT07392892Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerPhase 2/32031-07-222032-01-15+177 days
2026-09-29DeupsilocinNCT06564818"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"Phase 32026-082026-09-04+34 days
2026-09-29tulisokibartNCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)Phase 32026-08-012026-08-12+11 days
2026-09-26CapecitabineNCT05610163Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation and Continuing ResponsePhase 2/32026-09-302030-07-01+1370 days
2026-09-26RanibizumabNCT06305416A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular EdemaPhase 32025-102026-03-10+160 days
2026-09-26DeupsilocinNCT06605105Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)Phase 32028-03-152028-06-06+83 days
2026-09-26DeupsilocinNCT06793397A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPhase 32027-03-182027-06-07+81 days
2026-09-26Adebrelimab, Bevacizumab, SintilimabNCT06618664A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02)Phase 32026-092026-10+30 days
2026-09-26Nab-paclitaxel, Relacorilant (Lifyorli)NCT05257408Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerPhase 32025-03-242025-03-31+7 days
2026-09-26PonsegromabNCT06989437A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and FatiguePhase 2/32028-01-172028-01-23+6 days
2026-09-25EnvafolimabNCT05752136Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal AdenocarcinomaPhase 32025-042026-11-01+579 days
2026-09-25AnifrolumabNCT06455449A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)Phase 32027-05-142028-01-10+241 days
2026-09-25sildenafilNCT07462260Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)Phase 2/32026-042026-09-23+175 days
2026-09-25MethotrexateNCT07501507Methotrexate Treatment in Hand Osteoarthritis Refractory to Usual TreatmentsPhase 2/32027-102028-02+123 days
2026-09-25jaktinibNCT05861128Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)Phase 32025-122026-03-04+93 days
2026-09-25Dexamethasone, Mezigdomide, CarfilzomibNCT05552976A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)Phase 32026-07-182026-09-28+72 days
2026-09-25Capecitabine, Trastuzumab pamirtecan, Nab-paclitaxelNCT06018337A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)Phase 32026-062026-08-12+72 days
2026-09-25FinerenoneNCT05457283A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaPhase 32028-08-012028-08-07+6 days
2026-09-24Capecitabine, Docetaxel, Disitamab VedotinNCT04400695A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2Phase 32024-06-302027-12-31+1279 days
2026-09-24LitifilimabNCT05352919A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)Phase 32030-03-292032-05-03+766 days
2026-09-24Palbociclib, CetuximabNCT04966481Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 InhibitorPhase 32028-02-282029-02-28+366 days
2026-09-24Repotrectinib, CrizotinibNCT06140836A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)Phase 32026-03-132027-02-16+340 days
2026-09-24zanubrutinib, Pirtobrutinib, Acalabrutinib, IbrutinibNCT04662255Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Phase 32027-012027-11+304 days
2026-09-24Zongertinib, pemetrexed, PembrolizumabNCT06151574Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentPhase 32026-09-022026-12-10+99 days
2026-09-24Cabozantinib, NivolumabNCT07405164Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)Phase 32034-01-142034-04-22+98 days
2026-09-24AvelumabNCT03815643Avelumab Program Rollover StudyPhase 32026-08-212026-11-24+95 days
2026-09-24FinerenoneNCT07223502A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney DiseasePhase 32026-072026-09-17+78 days
2026-09-22Valsartan/amlodipine/chlorthalidone (AJU-C52)NCT06416865Efficacy and Safety of AJU-C52 in Essential Hypertension PatientsPhase 32022-12-122024-12-23+742 days
2026-09-22Dexamethasone, Lenalidomide, CarfilzomibNCT04096066A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for TransplantPhase 32026-01-012027-09-01+608 days
2026-09-22Tislelizumab, Nab-paclitaxelNCT06258811Neoadjuvant Immunochemotherapy for LAOSCCPhase 32026-12-302027-12-30+365 days
2026-09-22Rimegepant (Nurtec ODT)NCT07729462A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic MigrainePhase 32028-09-122028-10-21+39 days
2026-09-22DocetaxelNCT03691454Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric AdenocarcinomaPhase 2/32026-08-302026-09-30+31 days
2026-09-22Sacubitril/valsartanNCT03508739Glucagon-like Peptide-1 Metabolism and Acute Neprilysin InhibitionPhase 32026-06-012026-06-30+29 days
2026-09-22tocilizumabNCT07263776Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2Phase 32026-09-162026-09-18+2 days
2026-09-19Docetaxel, PembrolizumabNCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)Phase 32026-09-152026-11-20+66 days
2026-09-19MethotrexateNCT03371667To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With CorticosteroidsPhase 32024-122025-01-24+54 days
2026-09-18SerplulimabNCT07177443Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal CarcinomaPhase 32031-12-312035-12-31+1461 days
2026-09-18Lenalidomide, DaratumumabNCT04071457S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationPhase 32029-07-012032-09+1158 days
2026-09-18BexicaserinNCT06660394A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)Phase 32026-08-212026-12-31+132 days
2026-09-17BevacizumabNCT05798819A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerPhase 32025-05-012029-12-31+1705 days
2026-09-17Brexpiprazole (Rexulti)NCT05325645Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute SchizophreniaPhase 32026-022027-09+577 days
2026-09-16PF-06823859NCT05895786A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]Phase 32027-07-282030-07-29+1097 days
2026-09-16BlinatumomabNCT07223190A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic LeukaemiaPhase 32030-05-102031-12-30+599 days
2026-09-16OlverembatinibNCT06423911Study of Olverembatinib (HQP1351) in Patients With CML-CPPhase 32025-122027-06-30+576 days
2026-09-16Capecitabine, PembrolizumabNCT06901531A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerPhase 32027-03-312028-09-30+549 days
2026-09-16tenofovir alafenamide (Vemlidy)NCT05813964Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.Phase 32026-102027-12-31+456 days
2026-09-16Semaglutide (Ozempic)NCT05569772Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational DiabetesPhase 32029-062030-03+273 days
2026-09-16EsketamineNCT06051227Fentanyl OR Esketamine for Traumatic PAIN (FORE-PAIN) TrialPhase 32026-032026-08-06+158 days
2026-09-15Giredestrant, Palbociclib, Fulvestrant, Ribociclib, AbemaciclibNCT06065748A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Phase 32027-02-192028-04-20+426 days
2026-09-15Pivekimab Sunirine, Azacitidine, VenetoclaxNCT07581002A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)Phase 2/32032-052032-06+31 days
2026-09-12deucravacitinib, apremilastNCT04908189A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentPhase 32024-02-062024-11-07+275 days
2026-09-11TemozolomideNCT07349693Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent GlioblastomaPhase 2/32028-12-012029-03-30+119 days
2026-09-10Sodium zirconium cyclosilicateNCT06578533Keeping RAASi Treatment With Optimal Potassium ControlPhase 32025-07-302027-07-30+730 days
2026-09-10Azacitidine, VenetoclaxNCT06073730Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia PatientsPhase 32024-11-012025-12-30+424 days
2026-09-10ZiltivekimabNCT06118281ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackPhase 32026-12-142027-01-29+46 days
2026-09-10Umeclidinium, fluticasone furoate/umeclidinium/vilanterol, fluticasone furoate/vilanterol, Fluticasone FuroateNCT05757102A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaPhase 32027-01-222027-01-26+4 days
2026-09-09tofacitinibNCT06172361Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia RheumaticaPhase 32025-09-302026-05-30+242 days
2026-09-09Semaglutide (Ozempic)NCT07059377Semaglutide for Smoking Cessation in Patients With DiabetesPhase 32026-072026-12+153 days
2026-09-09bimekizumabNCT04436640A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisPhase 32026-08-072026-08-09+2 days
2026-09-05Methotrexate, CetuximabNCT05751512A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHNPhase 32025-082027-12+852 days
2026-09-05tilrekimigNCT07765888A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe EczemaPhase 32028-02-292028-03-10+10 days
2026-09-04Ivosidenib, Enasidenib, Revumenib, Azacitidine, Venetoclax, GilteritinibNCT03013998Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaPhase 2/32028-122032-12+1461 days
2026-09-04Pembrolizumab, CetuximabNCT07509099Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCCPhase 32030-09-302031-09-30+365 days
2026-09-04Tremelimumab, Bevacizumab, Rilvegostomig, AtezolizumabNCT06921785Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular CarcinomaPhase 32029-03-162030-03-15+364 days
2026-09-04Encorafenib, Binimetinib, PembrolizumabNCT04657991A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaPhase 32026-01-122026-10-30+291 days
2026-09-04Gemcitabine, Vemurafenib, pemetrexed, Entrectinib, Divarasib, Cobimetinib, Alectinib, Bevacizumab, AtezolizumabNCT03178552A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Phase 2/32026-10-312027-06-30+242 days
2026-09-04tezepelumabNCT07363642Phase 3b Study in Patients With Severe Asthma Treated With TezepelumabPhase 32027-08-072028-02-07+184 days
2026-09-04Pirfenidone (Esbriet)NCT07284602Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)Phase 32029-062029-11+153 days
2026-09-04PalbociclibNCT03820830Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerPhase 32026-07-272026-12+127 days
2026-09-03Tenofovir alafenamide/emtricitabineNCT05813964Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.Phase 32026-102027-12-31+456 days
2026-09-03DocetaxelNCT04540692Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast CancerPhase 32026-042027-04+365 days
2026-09-03VenetoclaxNCT05939180VA vs DA for Newly Diagnosed Hig-risk AMLPhase 2/32025-10-012026-06-13+255 days
2026-09-03Docetaxel, GemcitabineNCT07464145A Study of NDV-01 (Sustained-release Gemcitabine-docetaxel) in Participants With Non-muscle Invasive Bladder CancerPhase 32029-092029-12+91 days
2026-09-02Exemestane, Letrozole, Anastrozole, Tamoxifen (Soltamox)NCT05645536Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyPhase 32028-062030-03+638 days
2026-09-02SitagliptinNCT05972928Effect of Sitagliptin on Polycystic Ovarian Syndrome PatientsPhase 2/32023-10-302025-04-30+548 days
2026-09-02HydroxychloroquineNCT05287321The Efficacy of Aspirin Combined With Hydroxychloroquine Treatment in High Risk Pregnancies for PreeclampsiaPhase 32025-12-312026-12-31+365 days
2026-09-02Capecitabine, Zanidatamab, TislelizumabNCT05152147A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersPhase 32026-07-312026-09-30+61 days
2026-09-02Descartes-08NCT06799247Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia GravisPhase 32026-11-302026-12-30+30 days
2026-09-02SSGJ-611NCT06554847Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic DermatitisPhase 32025-10-122025-10-20+8 days
2026-09-01SHR-1819NCT06468956Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic DermatitisPhase 32026-03-312026-12-31+275 days
2026-08-29pemetrexed, Pembrolizumab, Nab-paclitaxelNCT06096844Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialPhase 32035-01-312039-04-01+1521 days
2026-08-29ivarmacitinibNCT04957550To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic ArthritisPhase 32024-11-132026-12-13+760 days
2026-08-29Docetaxel, Gemcitabine, Sacituzumab Govitecan, PembrolizumabNCT06524544A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerPhase 32028-12-312030-12-31+730 days
2026-08-29CamrelizumabNCT07235319PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPCPhase 32031-11-202032-04-16+148 days
2026-08-29PelacarsenNCT04023552Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVDPhase 32026-06-302026-07-16+16 days
2026-08-29apremilastNCT06088199A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque PsoriasisPhase 32026-08-062026-08-12+6 days
2026-08-28Brexpiprazole (Rexulti)NCT04569448Brexpiprazole Treatment for Bipolar I DepressionPhase 32025-022030-09+2038 days
2026-08-28DocetaxelNCT03691454Compare Neoadjuvant DOS Combined With Toripalimab Versus SOX Combined With Toripalimab in Locally Advanced Gastric AdenocarcinomaPhase 2/32022-06-302026-08-30+1522 days
2026-08-28vedolizumabNCT06337695Vedolizumab for the Prevention of ICI Related Diarrhea or Colitis in Patients With CancerPhase 2/32026-11-012030-12-01+1491 days
2026-08-28Capecitabine, GemcitabineNCT05314998Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification SignaturePhase 32031-01-012033-04-01+821 days
2026-08-28insulin glargineNCT05573477Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II DiabetesPhase 32024-012025-08-31+608 days
2026-08-28MB12, pemetrexed, PembrolizumabNCT06687369A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)Phase 32026-062026-08-31+91 days
2026-08-28Staccato AlprazolamNCT05077904A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged SeizuresPhase 32026-08-312026-09-30+30 days
2026-08-27Sotagliflozin (Inpefa)NCT06481891A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic CardiomyopathyPhase 32026-072027-01+184 days
2026-08-27OcrelizumabNCT06846281Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 32029-07-242029-07-25+1 day
2026-08-26Bevacizumab, AtezolizumabNCT04770896A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabPhase 32026-06-302026-10-14+106 days
2026-08-26GemcitabineNCT03533582Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After SurgeryPhase 32026-12-312027-03-31+90 days
2026-08-25Capecitabine, DocetaxelNCT03801876Comparing Proton Therapy to Photon Radiation Therapy for Esophageal CancerPhase 32026-12-212031-11-07+1782 days
2026-08-25Gemcitabine, Nab-paclitaxelNCT03257033Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPCPhase 32026-062027-06+365 days
2026-08-25EsomeprazoleNCT07326904Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux DiseasePhase 32024-10-102024-11-12+33 days

Showing the newest 300 of 323 moves. Each drug page lists every registry date for its own studies.

Source: ClinicalTrials.gov, each study's record. A month-only date (YYYY-MM) is read as the first of the month, and a date that only gained or lost its day is not counted as a move. Every move we have recorded, not only the last 180 days, is a free CSV on the open data page.